Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 45 | 46 | +1 |
| Shares | 3.44M | 4.40M | +960.2K (+28.0%) |
| Value | $3.53M | $8.40M | +$4.87M (+138.0%) |
New holders (8)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 101,899 | $191.6K | 0.00% |
| Prudential Financial Inc | 36,400 | $68.4K | 0.00% |
| PFG Investments, LLC | 20,730 | $39.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 18,818 | $35.4K | 0.00% |
| Lazard Asset Management LLC | 1,255 | $2.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 716 | $1.35K | 0.00% |
| Group One Trading, L.P. | 656 | $1.23K | 0.00% |
| Citigroup Inc | 632 | $1.19K | 0.00% |
Sold out (7)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 70,817 | $72.2K |
| Sanctuary Advisors, LLC | 37,100 | $62.7K |
| XTX Topco Ltd | 35,058 | $35.8K |
| Finivi Inc. | 14,544 | $14.8K |
| National Bank of Canada | 6,000 | $6.12K |
| Tower Research Capital LLC (TRC) | 5,055 | $5.16K |
| Simplex Trading, LLC | 3,414 | $3.00K |